iiinova — where your digital self keeps evolving

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Daniel Durocher @durocher1.bsky.social · 25/08/2026

New work from the lab! We report that DDIAS is a downstream effector of CIP2A-TOPBP1 in mitosis that suppresses ssDNA to preserve genome integrity. From the great @yiboxue.bsky.social and many collaborators! Free link: authors.elsevier.com/a/1nfiF3vVUP... Pay link: www.cell.com/molecular-ce...

Model of DDIAS acting in mitosis to suppress ssDNA

56118

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 24/08/2026

How do cancers regulate endoplasmic reticulum pH and stress? We show that the Golgi anion channel GPR89 plays a key role by translocating to the ER. GPR89 enhances mammary tumorigenesis and targeting GPR89 inhibits mammary cancers. Work led by the amazing Rico Ferro www.nature.com/articles/s41...

nature.com

The anion channel GPR89 is a tumor-specific dependency in breast cancer - Nature Communications

Oncogene-driven endoplasmic reticulum (ER) stress is common in cancer. Here, authors show breast cancers extend Golgi anion channel GPR89 to the ER to mitigate this stress, creating a potentially targ...

121

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Christian Zierhut @zierlab.bsky.social · 21/08/2026

Supremely excited to share our new paper in @natcellbio.nature.com With an updated genetic cGAMP reporter, we reveal that cGAS activation by DNA damage is a rare event, and that cGAS enrichment on intracellular structures cannot be taken as evidence of activation. www.nature.com/articles/s41...

nature.com

A versatile cGAMP reporter reveals principles of cGAS activation by DNA damage and chromosome instability - Nature Cell Biology

Lebrec et al. present a FRET-based cGAS reporter and show that cGAS activation by genotoxic stress is rare and uncoupled from micronuclei. The study implicates R-loop structures and subtypes of chroma...

97130

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Alex Radzisheuskaya @a-radzisheuskaya.bsky.social · 08/07/2026

1/ Very excited to share the first publication from my lab! In this work, we developed an efficient strategy to precisely mutate mammalian histone genes in their native genomic context using CRISPR prime editing: www.nature.com/articles/s41...

nature.com

Identifying critical lysines in mammalian histone H3 with high-throughput CRISPR prime editing - Nature Genetics

This study uses a precise and efficient clustered regularly interspaced short palindromic repeats (CRISPR) prime editing system to substitute lysine residues in histone H3, individually or in combinat...

1112044

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 30/05/2026

@arsenalfc.bsky.social a valiant loss. We took the fight to a skilful team and if were to loose, it wasn’t because we were poorer. Still crying at what might have been. We fight again.

010

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 21/05/2026

Bea has been a stalwart of research at the Breast Cancer Now Centre since its inception. Seeing her contribution recognised like this is great.

000

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 06/05/2026

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

nature.com

Two decades of PARP inhibitor synthetic lethality in cancer - Nature

The past two decades of PARP inhibitor synthetic lethality in cancer is explored.

01510

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Meier Lab ICR @meierlabicr.bsky.social · 09/03/2026

Our new study is out in Nature Communications. Using TNBC organoid mouse models, we show that necroptosis in both tumour and stromal compartments cooperatively drives effective responses to immunogenic cell death–based immunotherapy. 🔗 www.nature.com/articles/s41...

nature.com

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy - Nature Communications

Most advanced triple-negative breast cancers remain resistant to immunotherapy. Here, the authors discover that RIPK1-driven necroptosis in both tumor and stromal compartments is essential for effecti...

0175

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Joanna Loizou @loizoulab.bsky.social · 25/10/2025

Really pleased to have presented work on targeting GPR89 in breast cancer with @ricoferro.bsky.social from the Tutt and Lord labs as part of the ICRs Centre for Target Validation @icrlordlab.bsky.social at #Targets2025 in Boston @icr.ac.uk @breastcancernow.bsky.social

072

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Andrew Deans @genomestability.bsky.social · 13/10/2025

Ever wondered what S-phase tastes like? 3 lucky presenter prize winners will find out (+Amazon voucher!) at #ACDTM25. You can still register for this fantastic Melbourne meeting Oct 20-22. Official 10 year old taste tester: "lemon excision repair" is the best flavour www.australiancellcycle.org

0104

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

derek guy @dieworkwear.bsky.social · 29/08/2025

RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.

A photo of Jim O'Neil getting sworn in by RFK Jr. You can see a close-up of his tie.

The same tie on Otaa's website. The site shows the tie is made from 100% microfiber.

The label for Otaa'a ties. It says "Designed in Australia."

The back of the label. It says "100% Microfiber. Hand Made Made in China"

33679561343

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Sarah Moser @sarahmoser.bsky.social · 13/08/2025

Thrilled to share our latest work, just published in @nature.com ⬇ www.nature.com/articles/s41... We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors. 🧵 (1/8)

nature.com

NASP modulates histone turnover to drive PARP inhibitor resistance - Nature

PARP inhibitor treatment triggers histone release from the chromatin in cancer cells; consequently, targeting the histone chaperone NASP renders cells vulnerable to PARP inhibition.

38332

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 30/07/2025

With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t

rdcu.be

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers

Nature Communications - The RNA editing enzyme ADAR1 blocks interferon responses triggered by cytosolic RNA sensors, and has been proposed as a potential target in immuno-oncology. Here, the...

023

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Paperpile @paperpile.com · 09/07/2025

Academic writing is a craft. ✍️ You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well. Your writing is the first thing people see before they meet you. Make it count.

142

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Stephen John Sammut @stephensammut.bsky.social · 19/06/2025

Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️ 🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk #bcsm #ai #CancerResearch

5173

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Francesco Iorio @francescoiorio.bsky.social · 11/06/2025

🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR

humantechnopole.it

2nd European Cancer Dependency Map Symposium - Human Technopole

The 2nd European Cancer Dependency Map Symposium is a scientific event open to the national and international scientific community working in computational genomics, pharmacogenomics, and therapeutic ...

3219

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Francesco Iorio @francescoiorio.bsky.social · 11/06/2025

Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open! humantechnopole.it/en/trainings... youtu.be/x2erCuovGvc #EuroDepMap

youtu.be

1st European Cancer Dependency Map Symposium

YouTube video by Human Technopole

031

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 14/05/2025

Loving “pertomics”. Going to push the term “buffomics” too.

110

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 25/04/2025

We're looking for a Scientific Operations Project Manager to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...

jobs.icr.ac.uk

Scientific Operations Project Manager in Chelsea | The Institute of Cancer Research

View details and apply for this Scientific Operations Project Manager vacancy in Chelsea . Salary : Commencement on the salary range is subject to comparable skills and experience. Future p...

063

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/04/2025

The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer www.nature.com/articles/s41... ✅Sac-TMT significantly improved progression-free survival PFS

074

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Barbara Marte @barbmarte.bsky.social · 15/04/2025

this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.

15921

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 14/04/2025

Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...

jobs.icr.ac.uk

Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) in Chelsea | The Institute of Cancer Research

View details and apply for this Scientific Officer - Target Validation and DNA Damage Response Group (Prof Andrew Tutt) vacancy in Chelsea . Salary : Commencement on the salary range is s...

063

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Serena Nik-Zainal @serenanikzainal.bsky.social · 10/04/2025

PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻 A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet Brainchild of the amazing #GeneKoh (Sir Jeffrey Cheah ECR) Tweetorial below!! 👇 1/n www.nature.com/articles/s41...

nature.com

A redefined InDel taxonomy provides insights into mutational signatures - Nature Genetics

This paper describes a framework for classifying small insertions and deletions from genomic data and applies it to a large dataset comprising seven tumor types. The analysis highlights new insertion ...

23512

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Luijsterburglab @luijsterburglab.bsky.social · 09/04/2025

A must for all DNA repair aficionados! Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱 ✔️ Confirmed top speakers ✔️ Ample opportunities for talks & posters Don’t miss it: dnarepairmeeting-egmond2026.com

43719

Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research @icrlordlab.bsky.social · 04/04/2025

We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.

071

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

George Sflomos @georgesflomos.bsky.social · 29/03/2025

Super nice review on metastasis organo-tropism⬇️ the process where tumor cells preferentially spread to specific distant organs, and represents a critical aspect of cancer biology with profound implications for patient outcomes. #CDH1 www.cell.com/trends/cance...

cell.com

Regulation of metastatic organotropism

Metastasis is responsible for most cancer-related deaths. Different cancers have their own preferential sites of metastases, a phenomenon termed metastatic organotropism. The mechanisms underlying org...

1135

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Fusion Conferences @fusionconf.bsky.social · 25/03/2025

📢The programme for #DDRCT25 is now available! Visit our website to explore the exciting sessions, speakers, and key topics we have in store. ➡️Check it out here: fusion-conferences.com/conference/177

156

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Trevor Graham @trevorgraham.bsky.social · 21/03/2025

Ben O'Leary & I are looking for a #postdoc to join us in @cec-icr.bsky.social to work on collaborative @cancerresearchuk.org RadNet project about the interrelationship between genome & epigenome instability and radiotherapy response. Details & apply here: jobs.icr.ac.uk/vacancies/11... @icr.ac.uk

jobs.icr.ac.uk

Postdoctoral Training Fellow - Evolution & Translational Genomics in Sutton | The Institute of Cancer Research

View details and apply for this Postdoctoral Training Fellow - Evolution & Translational Genomics vacancy in Sutton. Salary: Dependent on relevant Postdoctoral experience. Future progre...

11522

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

Rossanese Lab @temt-icr.bsky.social · 18/03/2025

🚨We’re recruiting!🚨 Looking directly at my oncology drug discovery biology folks 👀 3️⃣ faculty-level biology posts, including leadership in drug discovery & target validation. Drug discovery experience a must, industry experience valued, you’ve gotta be in London. ICR.ac.uk/CCDDjobs for info/contact

Recruitment brochure featuring a picture of our Centre for Cancer Drug Discovery and the same web address from the main post.

088

Reposted by Chris Lord and Andrew Tutt’s Lab Institute of Cancer Research

marcelvanvugt.bsky.social @marcelvanvugt.bsky.social · 18/03/2025

Happy to post a new study on BioRxiv, where we show Integrated Stress Response activation as an off-target effect of multiple clinically evaluated WEE1 inhibitors. Team effort with the lab of Dan Durocher @durocher1.bsky.social and many others. www.biorxiv.org/content/10.1...

biorxiv.org

WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response

The WEE1 kinase negatively regulates CDK1/2 to control DNA replication and mitotic entry. Genetic factors that determine sensitivity to WEE1 inhibitors (WEE1i) are largely unknown. A genome-wide inser...

33112